Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Gastrointestinal Stromal Tumor (GIST) — Therapy by Mutation

First-line Second-line Later-line SECOND-LINE THIRD-LINE / LATER GIST by mutation KIT / PDGFRA-sensitive PDGFRA D842V SDH / NTRK / NF1 / BRAF Resected, high-risk After imatinib Later-line First-line Imatinib non-D842V ↗ Targeted Avapritinib D842V-specific ↗ Genotype TRK inhibitor / clinical trial genotype-directed ↗ Adjuvant Adjuvant imatinib ≥ 3 years risk-adapted ↗ Second-line Sunitinib KIT secondary mutation ↗ Third-line Regorafenib GRID ↗ Fourth-line Ripretinib INVICTUS ↗